These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 17174219)

  • 1. Anticoagulants and their reversal.
    Schulman S; Bijsterveld NR
    Transfus Med Rev; 2007 Jan; 21(1):37-48. PubMed ID: 17174219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversing anticoagulants both old and new.
    Warkentin TE; Crowther MA
    Can J Anaesth; 2002; 49(6):S11-25. PubMed ID: 12557411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of bleeding complications in the anticoagulated patient.
    Bhagirath VC; O'Malley L; Crowther MA
    Semin Hematol; 2011 Oct; 48(4):285-94. PubMed ID: 22000094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Reversal for heparins and new anticoagulant treatments].
    Kortchinsky T; Vigué B; Samama CM
    Ann Fr Anesth Reanim; 2013 Jan; 32(1):37-49. PubMed ID: 23273505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bleeding complications of anticoagulant therapy].
    Gumulec J; Kessler P; Procházka V; Brejcha M; Penka M; Zänger M; Machytka E; Klement P
    Vnitr Lek; 2009 Mar; 55(3):277-89. PubMed ID: 19378860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Andexanet Alfa, the Possible Alternative to Protamine for Reversal of Unfractionated Heparin.
    Maneno JN; Ness GL
    Ann Pharmacother; 2021 Feb; 55(2):261-264. PubMed ID: 32667214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation.
    Tanaka KA; Szlam F; Dickneite G; Levy JH
    Thromb Res; 2008; 122(1):117-23. PubMed ID: 17977586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography.
    Young G; Yonekawa KE; Nakagawa PA; Blain RC; Lovejoy AE; Nugent DJ
    Blood Coagul Fibrinolysis; 2007 Sep; 18(6):547-53. PubMed ID: 17762530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of drug-induced anticoagulation: old solutions and new problems.
    Dzik WS
    Transfusion; 2012 May; 52 Suppl 1():45S-55S. PubMed ID: 22578371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?
    Dickneite G; Hoffman M
    Thromb Haemost; 2014 Feb; 111(2):189-98. PubMed ID: 24136202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction of coagulopathy in warfarin associated cerebral hemorrhage.
    Aiyagari V; Testai FD
    Curr Opin Crit Care; 2009 Apr; 15(2):87-92. PubMed ID: 19300085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents.
    Levi M; Eerenberg E; Kamphuisen PW
    J Thromb Haemost; 2011 Sep; 9(9):1705-12. PubMed ID: 21729240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Old and new anticoagulants. Antidotes and measures for acute hemorrhaging and urgent interventions].
    Lancé M; Stessel B; Hamulyák K; Marcus MA
    Anaesthesist; 2010 Jan; 59(1):62, 64-8. PubMed ID: 19936577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel anticoagulants and the future of anticoagulation.
    Garcia D
    Thromb Res; 2009; 123 Suppl 4():S50-5. PubMed ID: 19303505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of protamine to rapidly reverse anticoagulant effect of unfractionated heparin in patients undergoing percutaneous coronary intervention.
    Patel AA; White CM; Coleman CI
    Conn Med; 2007 Feb; 71(2):93-5. PubMed ID: 17393902
    [No Abstract]   [Full Text] [Related]  

  • 18. Restoration of the normal coagulation process: advances in therapies to antagonize heparin.
    D'Ambra M
    J Cardiovasc Pharmacol; 1996; 27 Suppl 1():S58-62. PubMed ID: 8938285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of asymptomatic over-anticoagulation with oral vitamin K.
    Chirputkar SK; Poole HJ; McNeil RC; Tansey P; Etherington AM; Morrison C; Tait RC
    Br J Haematol; 2006 Nov; 135(4):591-2. PubMed ID: 17054668
    [No Abstract]   [Full Text] [Related]  

  • 20. [Influence of nonachlazin, riboxin and isoptin on the blood coagulation system and the anticoagulant effect of heparin].
    Shevchenko LV; Ovchinnikova LK; Zolotukhin SI
    Farmakol Toksikol; 1980; 43(4):389-95. PubMed ID: 7439373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.